Efficacy and Safety of Percutaneous Coronary Intervention for Elderly Patients in the Second-Generation Drug-Eluting Stent Era: The SHINANO Registry

Abstract

Background:

We evaluated the 1-year outcomes of percutaneous coronary intervention (PCI) for elderly patients (aged ≥ 80 years) in the second-generation drug-eluting stent (DES) era.

Methods and Results:

Between August 2012 and July 2013, 1923 consecutive patients (mean age, 71 ± 11 years; ≥80 years, 23%; men, 77%) who underwent 2250 elective/urgent PCI procedures were enrolled in the Shinshu Prospective Multicenter Analysis for Elderly Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention registry. The primary end point was major adverse cardiovascular events (MACEs; cardiovascular death, myocardial infarction, and stroke) at 1 year. The 1-year incidence of MACEs, cardiac death, and stroke was significantly higher in elderly patients than in nonelderly patients (12.4% vs 5.3%, P < .0001; 7.8% vs 2.2%, P < .0001; and 2.8% vs 1.3%, P = .033, respectively). However, no significant difference in elective PCI procedures was detected. In elderly patients, the incidence of cardiac death and target lesion revascularization was significantly lower for DES than for non-DES (2.7% vs 10.5%, P = .0001 and 4.1% vs 8.6%, P = .029, respectively).

Conclusion:

Although elderly patients had a significantly poorer prognosis than younger patients, the adverse events rate was comparable in those patients who underwent elective PCI in the second-generation DES era.

Keywords

elderly percutaneous coronary intervention coronary artery disease

Get full access to this article

View all access options for this article.

References

Miura

Soga

Doijiri

. et al. Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention. Circ J. 2013;77(1):89–95.

Daemen

Wenaweser

Tsuchida

. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667–668.

Mauri

Hsieh

Massaro

D’Agostino

Cutlip

. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356(10):1020–1029.

Lagerqvist

James

Stenestrand

Lindbäck

Nilsson

Wallentin

; SCAAR Study Group. Long-term outcomes with drug-eluting stent versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009–1019.

Gilard

Barragan

Noryani

. et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65(8):777–786.

Colombo

Chieffo

Frasheri

. et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64(20):2086–2097.

Miura

Miyashita

Motoki

. et al. In-hospital clinical outcomes of elderly patients (≥80 years) undergoing percutaneous coronary intervention. Circ J. 2014;78(5):1097–1103.

Cannon

Battler

Brindis

. et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001;38(7):2114–2130.

Vlaar

Lennon

Rihal

. et al. Drug-eluting stents in octogenarians: early and intermediate outcome. Am Heart J. 2008;155(4):680–686.

10.

de Belder

de la Torre Hernandez

Lopez-Palop

; et al. XIMA Investigators. A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: the XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly). J Am Coll Cardiol. 2014;63(14):1371–1375.

11.

Uthamalingam

Ahmado

Selvaraj

Dewey

Flynn

. Long term outcomes in octogenarians undergoing percutaneous coronary intervention: comparison of bare metal versus drug eluting stent. Int J Cardiol. 2015;179:385–389.

12.

Mangiacapra

Ricottini

Di Gioia

. et al. Comparison among patients ≥75 years having percutaneous coronary angioplasty using drug-eluting stents versus bare metal stents. Am J Cardiol. 2015;115(9):1179–1184.

13.

Goto

Nakai

Shizuta

; et al. CREDO-Kyoto Registry Cohort-2 Investigators. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol. 2014;114(1):70–78.

14.

Kimura

Morimoto

Nakagawa

Tamura

Kadota

Yasumoto

. et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;119(7):987–995.

15.

Tada

Byrne

Simunovic

. et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6(12):1267–1274.

16.

Palmerini

Sangiorgi

Valgimigli

. et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol. 2015;65(11):1092–1102.

17.

Jolly

Yusuf

Cairns

; et al. RIVAL Trial Group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377(9775):1409–1420.

18.

Yang

Qiao

. et al. A comparison of transradial and transfemoral approaches for percutaneous coronary intervention in elderly patients based on a propensity score analysis. Angiology. 2015;66(5):448–455.